-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $709

Benzinga·05/13/2026 15:05:11
Listen to the news
Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $640 to $709.